Pay in 4 interest-free payments of $22.50 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
5-3(6)1-2-4(7)8/h5-8H
PubMed Central PMCID: PMC3600382
Prolonged incubation (24 h) with Etomoxir produces diverse effects on the expression of several metabolic enzyme
ML364 (5-20 μM
InChi: InChI=1S/C18H18ClN5O3/c1-11(10-25)21-17(26)15-7-16(12-3-5-13(19)6-4-12)22-24(18(15)27)14-8-20-23(2)9-14/h3-9
ICI 118,551 Hydrochloride osuvastatin 5-3(6)1-2-4(7)8/h5-8HICI 118551, also known as ICI 118,551, is a selective beta 2 (2) adrenergic receptor antagonist. ICI 118551 binds to the 2 subtype with at least 100 times greater affinity than 1 or 3, the two other known subtypes of the beta adrenoceptor. The compound was developed by Imperial Chemical Industries, which was acquired by AkzoNobel in 2008. ICI 118,551 has no known therapeutic use in humans although it has been used widely in research to understand the
US$ 6273.75
US$ 8788.00
US$ 8132.25
US$ 6994.00